Trendlines Announces that Most Valuable Portfolio Company's Product on Schedule for Product Launch

MISGAV, Israel, 12 June 2017 -- The Trendlines Group Ltd. ("**Trendlines**" or "**the Group**") (SGX: 42T; OTCQX: TRNLY), a leading Israeli investment and innovation commercialization company, focused on early-stage, high growth innovation-based medical and agricultural technologies, today confirmed that the product developed by its Most Valuable Portfolio Company ("**the MVP Company**") is on schedule for launch in 2018.

In November 2014, the MVP Company referred to in our financial reports as our Most Valuable Portfolio Company, signed an asset purchase agreement with an independent third party ("**the Acquirer**") for the acquisition of the MVP Company's developed medical device product ("**Product**"). The acquisition price includes cash payment at closing, milestone payments, and royalties from future sales of the Product, as described in Note 8B of the Group's audited financial statements for the financial year ended 31 December 2016. In addition to a cash payment which was received at the initial closing in November, 2014, Trendlines Incubators – Israel Ltd., the Group's wholly-owned subsidiary, has additionally been paid approximately US$1.6 million in dividends, to date, upon the MVP Company's completion of certain milestones.

As Trendlines and the MVP Company are bound by a confidentiality agreement, additional details of the agreement cannot be disclosed. However, the Acquirer has provided the following updates and granted permission to release this information:

- The product launch continues to be on schedule in 2018.
- The Acquirer is currently in the process of establishing a high-volume manufacturing facility for the production of the Product.

Under the terms of the agreement, once sales of the Product begin, the Acquirer will make royalty payments to the MVP Company which, in turn, are expected to be distributed to the MVP Company's shareholders, including Trendlines Incubators – Israel Ltd.

Trendlines will provide further updates to the status of the MVP Company's Product as it gets closer to market launch and as authorized by the Acquirer.

Commenting on the confirmation of the product launch, Todd Dollinger, Chairman and CEO of Trendlines stated, "We are very pleased that the product launch is on-time and rapidly moving forward. From the corporate perspective of the Trendlines Group, the royalty stream which is scheduled to begin in 2018 when sales commence should contribute positively to our cash flow position in the future."

###

About Trendlines

Trendlines is an innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfil its mission to improve the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines' shares are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX International (OTCQX: TRNLY).

The Trendlines Group Ltd. (the "Company") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 26 November 2015. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor"). This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release. This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release. The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.